Upregulation of LncRNA BCYRN1 Promotes Tumor Progression and Enhances EpCAM Expression in Gastric Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Feb 14

PMID 29435146

Citations 15

Authors

Hao Ren

Xiaomin Yang

Yongmei Yang

Xiaoyu Zhang

Rui Zhao

Ran Wei

Xin Zhang

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Brain cytoplasmic RNA 1 (BCYRN1), along non-coding RNA, plays a critical role in various diseases, including some cancers. However, the expression of BCYRN1 and its roles in gastric carcinoma (GC) still remain unidentified. Thus, this study employed RT-qPCR to detect expression of BCYRN1 in 85 paired GC samples and adjacent normal tissues, and performed studies to explore effects of BCYRN1 in GC cells on cell proliferation, apoptosis and migration. We found BCYRN1 was significantly upregulated in GC samples, and its expression was positively correlated with advanced TNM stage ( = 0.0012) and tumor size ( = 0.027). Functionally, BCYRN1 knockdown by siRNA could inhibit cell proliferation, induce G1/G0 cell cycle arrest, increase apoptosis and impair migratory ability of AGS cells. Moreover, the results of RT-qPCR and western blotting indicated that knockdown of BCYRN1 notably decreased the expression of epithelial cell adhesion molecules (EpCAM). Otherwise, overexpression of BCYRN1 in GC cells (BGC-823 and SGC-7901) could reverse the effects of BCYRN1 knockdown. Taken together, our data indicate for the first time that BCYRN1 acts as an oncogenic lncRNA in GC progression and may be a potential therapeutic target in GC.

Citing Articles

LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer.

Arima J, Yoshino H, Fukumoto W, Kawahara I, Saito S, Li G Int J Mol Sci. 2024; 25(11).

PMID: 38892143 PMC: 11172611. DOI: 10.3390/ijms25115955.

Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma.

Han X, Li X, Zhao R, Ma H, Yu M, Niu X World J Gastrointest Oncol. 2023; 15(4):644-664.

PMID: 37123057 PMC: 10134208. DOI: 10.4251/wjgo.v15.i4.644.

Clinicopathological Significance and Prognostic Values of Long Noncoding RNA in Cancer Patients: A Meta-Analysis and Bioinformatics Analysis.

Han X, Wang Y, Zhao R, Zhang G, Qin C, Fu L J Oncol. 2022; 2022:8903265.

PMID: 35874631 PMC: 9303157. DOI: 10.1155/2022/8903265.

Long Noncoding RNA BCYRN1 Recruits BATF to Promote TM4SF1 Upregulation and Enhance HCC Cell Proliferation and Invasion.

Liu Y, Liu M, Jiao M, Jiang L, Fu X, Wang W Dis Markers. 2022; 2022:1561607.

PMID: 35730016 PMC: 9206761. DOI: 10.1155/2022/1561607.

The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma.

Morotti A, Cetani F, Passoni G, Borsari S, Pardi E, Guarnieri V Front Endocrinol (Lausanne). 2022; 13:869006.

PMID: 35586620 PMC: 9108332. DOI: 10.3389/fendo.2022.869006.

References

Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U . EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene. 2012; 32(5):641-50. DOI: 10.1038/onc.2012.75. View

Singh R, Gupta S, Peng W, Zhou N, Pochampally R, Atfi A . Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis. Cell Death Dis. 2016; 7(6):e2262. PMC: 5143396. DOI: 10.1038/cddis.2016.168. View

Shin H, Lee J, Kim Y, Jang S, Lee Y, Kim S . Knockdown of BC200 RNA expression reduces cell migration and invasion by destabilizing mRNA for calcium-binding protein S100A11. RNA Biol. 2017; 14(10):1418-1430. PMC: 5711455. DOI: 10.1080/15476286.2017.1297913. View

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Basile V, Vicente A, Martignetti J, Skryabin B, Brosius J, Kennedy J . Assignment of the human BC200 RNA gene (BCYRN1) to chromosome 2p16 by radiation hybrid mapping. Cytogenet Cell Genet. 1998; 82(3-4):271-2. DOI: 10.1159/000015117. View

Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H . The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012; 22(9):1775-89. PMC: 3431493. DOI: 10.1101/gr.132159.111. View

Zhang E, Yin D, Han L, He X, Si X, Chen W . E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs. Oncotarget. 2016; 7(17):23212-26. PMC: 5029621. DOI: 10.18632/oncotarget.6745. View

BALZAR M, Winter M, de Boer C, Litvinov S . The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl). 1999; 77(10):699-712. DOI: 10.1007/s001099900038. View

Guil S, Esteller M . Cis-acting noncoding RNAs: friends and foes. Nat Struct Mol Biol. 2012; 19(11):1068-75. DOI: 10.1038/nsmb.2428. View

10.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

11.

Bennett C, Chen Y, Vignali M, Lo R, Mason A, Unal A . Protein interaction analysis of senataxin and the ALS4 L389S mutant yields insights into senataxin post-translational modification and uncovers mutant-specific binding with a brain cytoplasmic RNA-encoded peptide. PLoS One. 2013; 8(11):e78837. PMC: 3823977. DOI: 10.1371/journal.pone.0078837. View

12.

Ikeo K, Oshima T, Shan J, Matsui H, Tomita T, Fukui H . Junctional adhesion molecule-A promotes proliferation and inhibits apoptosis of gastric cancer. Hepatogastroenterology. 2015; 62(138):540-5. View

13.

Tang Y, Cheung B, Atmadibrata B, Marshall G, Dinger M, Liu P . The regulatory role of long noncoding RNAs in cancer. Cancer Lett. 2017; 391:12-19. DOI: 10.1016/j.canlet.2017.01.010. View

14.

Zhao R, Zhu C, Li X, Cao W, Zong H, Cao X . BC200 LncRNA a potential predictive marker of poor prognosis in esophageal squamous cell carcinoma patients. Onco Targets Ther. 2016; 9:2221-6. PMC: 4846077. DOI: 10.2147/OTT.S99401. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Bremer E, Helfrich W . EpCAM-targeted induction of apoptosis. Front Biosci. 2008; 13:5042-9. DOI: 10.2741/3062. View

17.

Quinodoz S, Guttman M . Long noncoding RNAs: an emerging link between gene regulation and nuclear organization. Trends Cell Biol. 2014; 24(11):651-63. PMC: 4254690. DOI: 10.1016/j.tcb.2014.08.009. View

18.

Massague J . G1 cell-cycle control and cancer. Nature. 2004; 432(7015):298-306. DOI: 10.1038/nature03094. View

19.

Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):700-13. PMC: 4019373. DOI: 10.1158/1055-9965.EPI-13-1057. View

20.

Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O . The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 2004; 23(34):5748-58. DOI: 10.1038/sj.onc.1207610. View